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Identity 
Hugo: LOXL4 
Other names: LOXC (mouse); EER-7 (endothelial 
estrogen-regulated gene-7) 
Location: 10q24.2 
DNA/RNA 
Note: LOXL4 (lysyl oxidase-like 4) is a member of the 
lysyl oxidase (LOX) family. Its C-terminal region is 
conserved in all five members of this copper-dependent 
amine oxidase family and includes a copper-binding 
site, lysyl and tyrosine residues that form the 
lysyltyrosine-quinone cofactor (LTQ) and a cytokine 
receptor-like domain. The N-terminal region of LOXL4 
contains four scavenger receptor cysteine-rich (SRCR) 
domains and has homology with LOXL2 and LOXL3, 
but not with LOX or LOXL that do not contain these 
domains. The second SRCR domain contains a 13 
amino acid insertion that is unique to LOXL4. 
Description 
The LOXL4 genomic sequence is 14.095 kb with an 
open reading frame of 2.278 kb and a 5’UTR of 384 
bases. The TATA-box is at -25 and the TRE sequence, 
TGACTCA (TPA-responsive element), is at -75. The 
GATA domain is located at -113 and -669, and the 
RFX1 transactivator binding site, GGAA, is found at -
149. Sp1 transcription factor consensus sequence, 
GGCGGC, is at -181, CCAAT (CP1-factor) at -257 and 
-892 and the repetitive sequence motif GAAA at -310 
and 329. No GC box is present in the promoter region. 
Transcription 
The 14 exons of the LOXL4 gene make up an mRNA 
of 3.877 kb with a coding region of 2.278 kb. 
Transcriptional start site is at +384 upstream of the 
translation initiation codon (ATG). The first stop codon 
(TGA) is at position 14.480. In the 3’UTR there is a 
1230 bp untranslated trailer sequence and two 
consensus polyadenylation signals have been located 
30 bp and 322 upstream of the poly-A tail. 
Protein 
Note: Western blot analysis of HT-1080 cells detected 
the recombinant and secreted LOXL4 form as slightly 
larger than the cellular 85 kDa form probably due to 
glycosylation or other modifications, some of which 
may be cell type dependent. 
Description 
The predicted LOXL4 protein is 756 amino acids 
including a 24 amino acid signal peptide, with a 
molecular mass of approximately 84.5 kDa. 
Expression 
In tissues the LOXL4 mRNA is expressed in the 
placenta, trachea, lung, kidney, pancreas, testis, aorta 
liver, fetal liver and at lover levels in several other 
tissues that include the heart, skeletal muscle, spleen, 
prostate, ovary, small intestine, colon, bladder, and 
thyroid, adrenal, salivary and mammary glands. 
LOXL4 mRNA was also reported in vocal cord, 
laryngeal, hypopharyngeal, parotid and oropharyngeal 
carcinoma tumor biopsies. The LOXL4 mRNA was 
reported in cultured fibroblasts, smooth muscle cells, 
MDA-MB-231 breast cancer and osteosarcoma (OHS) 
cells. Both mRNA and immunohistochemistry analyses 
demonstrated LOXL4 expression in head and neck 
squamous cell carcinoma (HNSSC) tissues and cultured 
cell lines. No mRNA expression was detected in HCT-
116 and DLD-1 colon, MCF7, T47D and Hs578T 
breast and DU-145 prostate cancer lines. 
The mouse homologue of LOXL4, reported as LOXC, 
was identified as a mRNA expressed in calcified 
ATDC5 cells, MC3T3-E1 cells, C3H10T1/2 embryonic 
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fibroblast and myoblastic C2C12 cells. Up-regulation 
of the LOXL4 mRNA (EER-7) was reported 100-fold 
in human umbilical vein endothelial cells (HUVECs) 
transfected with estrogen receptor (alpha and beta) in 
response to treatment with 17beta-estrogen. 
Localisation 
The recombinant LOXL4 protein in human HT-1080 
fibrosarcoma cell line localized both intra- and 
extracellularly. In HNSCC, LOXL4 
immunohistochemical staining was prevalently 
cytoplasmic in poorly differentiated cases with 
increasing perinuclear staining in well-differentiated 
areas. In HTB-43 pharyngeal SCC cells LOXL4 
staining revealed a punctate pattern within cells with 
perinuclear enrichment. This pattern suggested 
containment of LOXL4 in the endomembrane sytem of 
cells at sites of synthesis and vesicular transport for 
secretion at the cell surface. Flow cytometry (FACS) 
analysis demonstrated that approximately 15% of these 
cells had LOXL4 localized on their surface. In contrast, 
LOXL4 expression was not detected (or only to a very 
low extent) in cultured normal epithelial cells derived 
from oral mucosa samples. 
Function 
LOXL4 may function as an active amine oxidase, as 
betaAPN (beta-aminopropionitrile) inhibitable 
enzymatically active recombinant human LOXL4 was 
generated in an E. coli expression system and 
positively evaluated for its catalytic activity with a 
diamine substrate. The mouse homologue of LOXL4, 
LOXC, showed similar betaAPN inhibitable catalytic 
activity when tested using a collagen substrate. 
Homology 
LOXL4 has homology with the C-terminal domains to 
LOX, LOXL1, LOXL2 and LOXL3 and homology 
with the four N-terminal SRCR domains of LOXL2 
and LOXL3. 
Implicated in 
Breast cancer invasion 
Note: LOXL4 mRNA was expressed in MDA-MB-231 
highly invasive breast cancer cells, but not in poorly 
invasive and non-metastatic breast cancer cells MCF7 
and T47D. 
Disease 
Breast cancer. 
Human head and neck squamous cell 
carcinoma (HNSSC) 
Note: LOXL4 mRNA was detected in 16 HNSSC cell 
lines, obtained from recurrent and primary tumors, 
whereas no expression was detected in normal 
epithelial cells. LOXL4 was also found over-expressed 
in 71% of invasive HNSSC tumors and primary tumors 
of the glottic larynx, parotic gland, oropharynx and 
nose synus, primary and metastatic tumors of the 
larynx, hypopharynx and tongue and metastatic tumor 
of the thyroid gland and in 90% of primary or 
metastatic HNSSC cell lines. 
Disease 
Invasive head and neck carcinoma. 
Prognosis 
Significant correlation was found between LOXL4 
expression and regional lymph node metastases and 
strong LOXL4 expression was present in metastatic 
HNSCC cell lines. There is no information regarding 
LOXL4 expression in distant metastases as patients 
with distant metastases are predominantly treated not 
surgically, but with radio- and/or chemotherapy. 
Cytogenetics 
Isochromosome i(10)(q10) was found associated with 
an amplification of the LOXL4 gene locus at 10q24 in 
a subset of interphase nuclei in UTSCC19A and 
HLAC78 head and neck carcinoma cells. 
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